With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations

Mumbai/New Delhi : Supriya Lifescience Ltd., a cGMP-compliant business and a leading manufacturer of Active Pharmaceutical Ingredients (APIs), announced that its Ambernath facility has been awarded the WHO Good Manufacturing Practices (GMP) certification, marking a significant milestone in the Company’s growth journey. The certification follows a rigorous audit and now enables Supriya to commence commercial manufacturing and sale of formulations from the facility.

The WHO GMP approval is a turning point for Supriya, as the Ambernath site has been developed as a cornerstone of its expansion beyond APIs into value-added formulations. The facility is designed to produce injectables, tablets, capsules, and inhalation dosages, with a projected revenue potential of nearly Rs 500 crore at peak capacity. Importantly, margins from this business are expected to be higher than the Company’s established API operations.

According to the FY 2024-25 Annual Report, capacity creation at Ambernath has been one of Supriya’s principal initiatives. With the WHO GMP certification in place, the facility can now supply to WHO-listed and regulated global markets, accelerating the Company’s formulations strategy. Together with the Lote Parshuram API site, the expansion takes Supriya’s overall manufacturing capacity to over 1,020 KL, strengthening operational flexibility and asset utilization.

Commenting on the development, Dr. Satish Wagh, Executive Chairman & Whole -Time Director, Supriya Lifescience Ltd. said, “Receiving the WHO GMP certification for Ambernath is a defining achievement for Supriya Lifescience. It validates our quality standards and unlocks the opportunity to scale our formulations business from a state-of-the-art facility. This expansion strengthens our global presence and positions us for sustained growth in higher-margin segments.”

The Ambernath site is also equipped to support R&D, pilot development, and contract development and manufacturing (CDMO/CMO) services, reinforcing Supriya’s ambition to evolve into a diversified pharmaceutical company. The certification and expansion reflect the Company’s focus on regulatory excellence, innovation, and long-term value creation for stakeholders.